LISCURE BIOSCIENCES
LISCure Biosciences is a developer of bacteria-mediated immunotherapy designed to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases. The company currently has seven pipelines of medicine and two pipelines of health-functioning food and is considering the introduction of two more pipes.
LISCURE BIOSCIENCES
Industry:
Biotechnology Health Care
Founded:
2018-12-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.liscure.bio
Total Employee:
1+
Status:
Active
Contact:
02-3443-1800
Total Funding:
5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apache Mobile Non Scaleable Content Google Apps For Business Cloudflare JS CDN JS AJAX Libraries API
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Current Employees Featured
Hwaseop Chin Co-Founder & Chief Executive Officer @ LISCure Biosciences
Co-Founder & Chief Executive Officer
2018-12-01
Junyoung Kil Chief Financial Officer @ LISCure Biosciences
Chief Financial Officer
2018-12-01
Founder
Investors List
KB Securities
KB Securities investment in Seed Round - LISCure Biosciences
Shinhan Investment
Shinhan Investment investment in Seed Round - LISCure Biosciences
NHN Investment
NHN Investment investment in Seed Round - LISCure Biosciences
Official Site Inspections
http://www.liscure.bio Semrush global rank: 4.34 M Semrush visits lastest month: 986
- Host name: 183.111.169.45
- IP address: 183.111.169.45
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "LISCure Biosciences"
LISCure
PR LISCure Biosciences Announces FDA Clearance of IND Application to Init.. FEB 29 2024 14:00 GMT- Represents first ever live biotherapeutic product to receive IND clearance for PSC …See details»
LISCure Biosciences - Crunchbase Company Profile & Funding
LISCure Biosciences is a developer of bacteria-mediated immunotherapy designed to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases. The company …See details»
LISCure Biosciences 2025 Company Profile: Valuation, …
LISCure Biosciences General Information Description. Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer. The …See details»
LISCure Biosciences Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for LISCure Biosciences Inc. of Seongnam, Gyeonggi. Get the latest business insights from Dun & …See details»
LISCure Biosciences - Products, Competitors, Financials, Employees ...
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient. Mar 20, 2025. News provided by Share this article Share toX …See details»
LISCure Biosciences Overview | SignalHire Company Profile
LISCure Biosciences is a private company that has been in the industry for 6 years. The company currently specializes in the Pharmaceuticals, Biotechnology areas. ... Organization Website: …See details»
LISCure Bioscience Co. Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore LISCure Bioscience Co. Ltd. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 7 news, Disease Domain:Nervous System Diseases ...See details»
LISCure Biosciences - CipherBio
LISCure Biosciences is a developer of bacteria-mediated immunotherapy designed to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases. The company …See details»
LISCure Company Profile - Office Locations, Competitors ... - Craft
LISCure is a biotech company that researches and develops bacteria-mediated immunotherapy. LISCure develops a “bacteria-mediated immunotherapy” that can be used to treat people by …See details»
LISCure - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 23, 2025 LISCure - Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases. Raised a total funding of $26M over 2 rounds from 3 investors. ... Website: …See details»
LISCure
LISCure Biosciences Provides Novel Therapeutics to Patients with Refractory Diseases Using the LMT Platform . LISCure is developing novel therapeutics using proprietary microbiota bank, …See details»
Liscure Biosciences Inc. - Specialist In Therapeutic Paradigm With ...
LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.” Bacteria-mediated …See details»
South Korea-based biotech startup LISCure Biosciences secures …
Feb 26, 2021 LISCure is developing the world’s first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for …See details»
LISCure Biosciences - Contacts, Employees, Board Members
LISCure Biosciences is a biotech company that researches and develops bacteria-mediated immunotherapy. New. Resources. Advanced Search ... Experience the new Crunchbase, …See details»
LISCure, the first Korean biotech company receiving equity …
Jul 26, 2021 LISCure plans to enter the global clinical trial for NASH candidate as well as auto-immune disease candidate in the second half of this year, and to initiate clinical trial in the US …See details»
LISCure
LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.” About LeadershipSee details»
LISCure Biosciences Secures World’s First Regulatory Approval for …
Mar 21, 2025 LISCure Biosciences Inc. ("LISCure") announced on the 2025 Feb that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, …See details»
BIO Statement on Resignation of Peter Marks from the FDA
1 day ago John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the …See details»
LISCure
Mar 4, 2024 PR LISCure Biosciences Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of LB-P8 for Primary Sclerosing Cholangitis ... please visit www.liscure.bio, or …See details»
LISCure
Constructed according to LISCure microbial resource management system LISCure Whole-Genome Sequence (WGS) & Microbiome Database Containing proprietary high-quality …See details»